Neuronetics Reveals Revised Legal Opinion For $27.7 Million Financing Tied To Debt Repayment
The previously priced share offering would help repay loans under a facility carrying an 11.5% interest rate as of September 30.
Neuronetics, which makes office-based brain-stimulation treatment systems, has now disclosed a replacement legal opinion in an amended SEC report filed Thursday for its previously announced offering, expected to net approximately $27.7 million. The amendment replaces counsel’s opinion and consent from the original report, also filed Thursday.
Share Sale To Help Repay Loans
Neuronetics priced 18,750,000 common shares at $1.60 each Tuesday under an agreement with William Blair, the firm representing the underwriters. All the shares are being sold by Neuronetics.
The underwriters have a 30-day option to buy 2,812,500 additional shares on the same terms. Neuronetics estimates net proceeds would reach $31.9 million if that option is fully exercised, after underwriting charges and estimated offering expenses.
The company intends to direct part of the money toward its Perceptive credit facility, which had $65 million outstanding in principal as of September 30. The loan carried an 11.5% interest rate on that date and matures July 25, 2029.
Part of the planned repayment relates to $10 million borrowed August 1, 2025. Neuronetics prepaid $5 million of those loans in March 2026. Other intended uses include research, sales and marketing, potential acquisitions or new healthcare practices, inventory, working capital and capital spending.
Lender Relief Has A Deadline
Neuronetics signed a credit-agreement change on November 5 that would reduce certain revenue requirements if its conditions are met. Those include at least $15 million in loan prepayments, along with interest, fees and expenses.
The company anticipates that satisfying the conditions would address the going-concern risk identified in recent quarterly filings—the risk that it may be unable to keep operating.
Neuronetics sells its NeuroStar Advanced Therapy System and recurring treatment sessions, mainly to U.S. psychiatrists. The non-invasive treatment stimulates brain areas associated with mood and is FDA-cleared for major depressive disorder, adult obsessive-compulsive disorder and anxiety symptoms in adults with depression.
The company also operates the Greenbrook clinic network, with 93 treatment centers. Clinic revenue and treatment sessions generate most of its revenue, which totaled $149.2 million in 2025.
Counsel Replaces The Share Opinion
Ballard Spahr, the company’s offering counsel, supplied the replacement legal opinion. It says the shares are authorized and will be validly issued when delivered and paid for under the underwriting agreement.
The amended report describes the option shares as additional to the 18,750,000 base shares. The replacement opinion describes its 18,750,000-share total as including up to 2,812,500 option shares.
The lender agreement change will automatically terminate unless its conditions are met or waived by November 30.
Sources
- 8-K/A Filing (Amendment) — Neuronetics, Inc. (STIM) — SEC EDGAR
- Original 8-K — Neuronetics, Inc. (filed 2026-11-12) — SEC EDGAR
- Exhibit d520791dex51.htm — Neuronetics, Inc. 8-K exhibit — SEC EDGAR
- Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock — Yahoo Finance
- Neuronetics stock tumbles 10% on stock offering launch — Yahoo Finance
- Neuronetics Announces Pricing of $30 Million Underwritten — globenewswire.com
- Neuronetics Announces Proposed Public Offering of Common — globenewswire.com